Evofem Biosciences Revenue and Competitors
Estimated Revenue & Valuation
- Evofem Biosciences's estimated annual revenue is currently $23.3M per year.
- Evofem Biosciences's estimated revenue per employee is $394,068
- Evofem Biosciences's total funding is $470.8M.
Employee Data
- Evofem Biosciences has 59 Employees.
- Evofem Biosciences grew their employee count by -46% last year.
Evofem Biosciences's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Staff | Reveal Email/Phone |
2 | CEO | Reveal Email/Phone |
3 | Head Human Resources ► Women’s Health Biosciences Company | Reveal Email/Phone |
4 | VP Technical Operations | Reveal Email/Phone |
5 | SVP, Investor Relations | Reveal Email/Phone |
6 | Director, SEC Reporting and Operational Accounting | Reveal Email/Phone |
7 | Chief Financial Officer | Reveal Email/Phone |
8 | Director, Accounting Operations | Reveal Email/Phone |
9 | Director Information Technology | Reveal Email/Phone |
10 | Strategic Market Director | Reveal Email/Phone |
Evofem Biosciences Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Evofem Biosciences?
Evofem (NASDAQ: EVFM) is a clinical-stage specialty biopharmaceutical company committed to improving the health and well-being of women throughout the world by addressing women's unmet medical needs through the discovery, development and commercialization of innovative, next generation women's healthcare products. Evofem's lead product candidate, Amphora, is a hormone-free, on demand, woman-controlled vaginal gel currently in a Phase 3 clinical trial as a contraceptive and in a Phase 2b trial for the prevention of urogenital transmission of chlamydia in women. In addition, Evofem recently completed a Phase 1 trial of its MPT vaginal gel for the reduction of recurrence of BV and is currently designing a Phase 2b trial for this indication. The successful development and commercialization of Amphora for contraception will create a platform for Evofem to advance its supplemental indications and deliver value for patients and shareholders alike.
keywords:N/A
$470.8M
Total Funding
59
Number of Employees
$23.3M
Revenue (est)
-46%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Evofem Biosciences News
Four analysts have made estimates for Evofem Biosciences' earnings, with the lowest EPS estimate coming in at ($0.24) and the highest estimate...
Four analysts have made estimates for Evofem Biosciences' earnings, with the lowest EPS estimate coming in at ($0.24) and the highest estimate...
Evofem Biosciences regains approval for Nasdaq listing compliance ... Evofem Biosciences (NASDAQ:EVFM) rallies 18.7% higher premarket after...
Evofem Biosciences regains approval for Nasdaq listing compliance ... Evofem Biosciences (NASDAQ:EVFM) rallies 18.7% higher premarket after...
Other Companies in San Diego
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $7.4M | 59 | -20% | $20M |
#2 | $6.4M | 59 | 2% | N/A |
#3 | $10.9M | 59 | -25% | N/A |
#4 | $11.2M | 59 | 9% | N/A |
#5 | $14.3M | 59 | -12% | N/A |